Every 10-Q that CYTODYN INC (CYDY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CYDY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYDY filings page.
CytoDyn Inc. (CYDY) reported a net loss of $19.936 million for the three months ended August 31, 2026, versus $5.540 million a year earlier. Operating expenses were $6.577 million, including $4.521 million in research and development; net cash used in operations was $7.726 million. Cash and cash equivalents were $16.359 million at August 31, 2026. Management said its $950.4 million accumulated deficit and other factors raise substantial doubt about continuing as a going concern.
The company completed a private offering on August 28, 2026, selling approximately 77.4 million units for approximately $16.2 million in cash; each unit included one common share and one warrant. The $0.20889 unit price was 90% of intraday VWAP at the August 28 close. Approximately $14.0 million for approximately 67.1 million units had been remitted by August 31, 2026. The final closing triggered a $12.272 million non-cash loss on note extinguishment.
In September 2026, a portion of the April 23, 2021 note was partitioned into a new note with approximately $1.0 million in principal and exchanged concurrently for approximately 4.9 million shares. CytoDyn reported preliminary approval of an agreement in principle to settle the securities class action, with proposed payment to the class of $500,000 in cash and 49 million shares, subject to final documentation, court approval, and other conditions. A hearing to consider final approval is scheduled for November 2, 2026.
CytoDyn Inc. reported a much larger net loss for the quarter ended November 30, 2025 as it booked a sizable legal settlement accrual and continued funding development of its antibody leronlimab for cancer. Quarterly net loss was $22.6M versus $4.8M a year earlier, driven mainly by a $16.6M legal settlement loss. For the first six months, the company lost $28.1M compared with prior-year profit that was boosted by a one-time clinical expense return.
Cash and cash equivalents fell to $5.0M while current liabilities reached $85.1M, including convertible notes and accrued interest. Management states that recurring losses, an accumulated deficit of about $915.9M, and looming obligations raise substantial doubt about CytoDyn’s ability to continue as a going concern without new financing. To access capital, the company put in place a standby equity purchase agreement allowing sales of up to $30M of stock and shareholders approved an increase in authorized common shares to 2.25 billion.
CytoDyn, Inc. reported a quarterly filing that raises substantial doubt about its ability to continue as a going concern and notes that its consolidated financial statements omit any adjustments that might be necessary if the company is unable to continue. The company disclosed a reduced outstanding balance on a note to $35.4 million after partitioned notes and described prior conversions and exchanges that produced millions of shares of common stock, including approximately 7.5 million shares issued in one transaction and a cashless warrant exercise for 23.1 thousand shares.
The company disclosed significant equity plan activity: the Amended and Restated 2012 Equity Incentive Plan covered 79.3 million and 66.8 million shares at August 31, 2025 and May 31, 2025, respectively, with an automatic 1% evergreen increase on June 1, 2025. Stock-based compensation expense uses Black-Scholes with a weighted-average fair value of $0.26 per option for grants in the three months ended August 31, 2025. Operating lease costs were approx. $31.0 thousand for the quarter. The company is evaluating multiple FASB ASUs affecting disclosure and tax reporting with varying effective dates through December 15, 2027.